Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Combined GLP-1, Oxyntomodulin, and Peptide YY Improves Body Weight and Glycemia in Obesity and Prediabetes/Type 2 Diabetes: A Randomized, Single-Blinded, Placebo-Controlled Study.

Behary P, Tharakan G, Alexiadou K, Johnson N, Wewer Albrechtsen NJ, Kenkre J, Cuenco J, Hope D, Anyiam O, Choudhury S, Alessimii H, Poddar A, Minnion J, Doyle C, Frost G, Le Roux C, Purkayastha S, Moorthy K, Dhillo W, Holst JJ, Ahmed AR, Prevost AT, Bloom SR, Tan TM.

Diabetes Care. 2019 Aug;42(8):1446-1453. doi: 10.2337/dc19-0449. Epub 2019 Jun 8.

2.

Type 2 diabetes remission 2 years post Roux-en-Y gastric bypass and sleeve gastrectomy: the role of the weight loss and comparison of DiaRem and DiaBetter scores.

Pucci A, Tymoszuk U, Cheung WH, Makaronidis JM, Scholes S, Tharakan G, Elkalaawy M, Guimaraes M, Nora M, Hashemi M, Jenkinson A, Adamo M, Monteiro MP, Finer N, Batterham RL.

Diabet Med. 2018 Mar;35(3):360-367. doi: 10.1111/dme.13532. Epub 2017 Nov 21.

3.

Roles of increased glycaemic variability, GLP-1 and glucagon in hypoglycaemia after Roux-en-Y gastric bypass.

Tharakan G, Behary P, Wewer Albrechtsen NJ, Chahal H, Kenkre J, Miras AD, Ahmed AR, Holst JJ, Bloom SR, Tan T.

Eur J Endocrinol. 2017 Dec;177(6):455-464. doi: 10.1530/EJE-17-0446. Epub 2017 Aug 30.

4.

Redefining the stress cortisol response to surgery.

Khoo B, Boshier PR, Freethy A, Tharakan G, Saeed S, Hill N, Williams EL, Moorthy K, Tolley N, Jiao LR, Spalding D, Palazzo F, Meeran K, Tan T.

Clin Endocrinol (Oxf). 2017 Nov;87(5):451-458. doi: 10.1111/cen.13439. Epub 2017 Aug 30.

5.

The Effect of a Subcutaneous Infusion of GLP-1, OXM, and PYY on Energy Intake and Expenditure in Obese Volunteers.

Tan T, Behary P, Tharakan G, Minnion J, Al-Najim W, Albrechtsen NJW, Holst JJ, Bloom SR.

J Clin Endocrinol Metab. 2017 Jul 1;102(7):2364-2372. doi: 10.1210/jc.2017-00469.

6.

Limitations of the DiaRem Score in Predicting Remission of Diabetes Following Roux-En-Y Gastric Bypass (RYGB) in an ethnically Diverse Population from a Single Institution in the UK.

Tharakan G, Scott R, Szepietowski O, Miras AD, Blakemore AI, Purkayastha S, Ahmed A, Chahal H, Tan T.

Obes Surg. 2017 Mar;27(3):782-786. doi: 10.1007/s11695-016-2368-9.

7.

Psychological characteristics, eating behavior, and quality of life assessment of obese patients undergoing weight loss interventions.

Miras AD, Al-Najim W, Jackson SN, McGirr J, Cotter L, Tharakan G, Vusirikala A, le Roux CW, Prechtl CG, Scholtz S.

Scand J Surg. 2015 Mar;104(1):10-7. doi: 10.1177/1457496914543977. Epub 2014 Jul 22.

8.

Coinfusion of low-dose GLP-1 and glucagon in man results in a reduction in food intake.

Cegla J, Troke RC, Jones B, Tharakan G, Kenkre J, McCullough KA, Lim CT, Parvizi N, Hussein M, Chambers ES, Minnion J, Cuenco J, Ghatei MA, Meeran K, Tan TM, Bloom SR.

Diabetes. 2014 Nov;63(11):3711-20. doi: 10.2337/db14-0242. Epub 2014 Jun 17.

9.

Emerging therapies in the treatment of 'diabesity': beyond GLP-1.

Tharakan G, Tan T, Bloom S.

Trends Pharmacol Sci. 2011 Jan;32(1):8-15. doi: 10.1016/j.tips.2010.10.003. Epub 2010 Dec 3. Review.

PMID:
21130506
10.

Modifying an immunogenic epitope on a therapeutic protein: a step towards an improved system for antibody-directed enzyme prodrug therapy (ADEPT).

Mayer A, Sharma SK, Tolner B, Minton NP, Purdy D, Amlot P, Tharakan G, Begent RH, Chester KA.

Br J Cancer. 2004 Jun 14;90(12):2402-10.

Supplemental Content

Loading ...
Support Center